FDA Approves Trastuzumab Biosimilar

Area of Science:

• Oncology
• Pharmacology

Background:

• The development of biosimilars is crucial for expanding patient access to targeted cancer therapies.
• Trastuzumab is a well-established monoclonal antibody for HER2-positive cancers.

Purpose of the Study:

• To announce the FDA approval of trastuzumab-dkst as a biosimilar.
• To indicate the approved indications for trastuzumab-dkst.

Main Methods:

• FDA regulatory review process.
• Assessment of analytical, clinical, and non-clinical data for biosimilarity.

Main Results:

• FDA approval of trastuzumab-dkst on December 1.
• Designation as the second approved cancer biosimilar.
• Approved for treatment of HER2-positive breast cancer.
• Approved for treatment of metastatic stomach cancer.

Conclusions:

• Trastuzumab-dkst provides a new biosimilar treatment option for patients with HER2-positive breast and metastatic stomach cancers.
• This approval signifies progress in the availability of affordable biologic cancer medications.